Phase Ii trial of acivicin in malignant mesothelioma
Falkson, G.; Vorobiof, D.A.; Simson, I.W.; Borden, E.C.
Cancer Treatment Reports 71(5): 545-546
1987
ISSN/ISBN: 0361-5960 PMID: 3567981 Document Number: 293548
Document emailed within 1 workday
Related Documents
Kelsen, D.; Gralla, R.; Cheng, E.; Martini, N. 1983: Vindesine in the treatment of malignant mesothelioma: a phase Ii study Cancer Treatment Reports 67(9): 821-822Loggie, B.W.; Fleming, R.A.; McQuellon, R.P.; Russell, G.B.; Geisinger, K.R.; Levine, E.A. 2001: Prospective trial for the treatment of malignant peritoneal mesothelioma American Surgeon 67(10): 999-1003
Sørensen, P.G.; Bach, F.; Bork, E.; Hansen, H.H. 1985: Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma Cancer Treatment Reports 69(12): 1431-1432
Carmichael, J.; Atkinson, R.J.; Calman, K.C.; Mackie, R.M.; Naysmith, A.M.; Smyth, J.F. 1982: A multicentre phase II trial of vindesine in malignant melanoma European Journal of Cancer and Clinical Oncology 18(12): 1293-1295
Wang, J.; Zhang, H.; Sun, Y. 1996: Results of phase II clinical trial of vindesine in the treatment of malignant tumors Zhonghua Zhong Liu Za Zhi 18(4): 285-288
Thigpen, J.T.; Al-Sarraf, M.; Hewlett, J.S. 1979: Phase Ii trial of dianhydrogalactitol in metastatic malignant melanoma: a Southwest Oncology Group study Cancer Treatment Reports 63(4): 525-528
Scherpereel, A. 2009: Malignant mesothelioma La Revue du Praticien 59(6): 751-755
Kensler, T.W.; Reck, L.J.; Cooney, D.A. 1981: Therapeutic effects of acivicin and N-(phosphonacetyl)-L-aspartic acid in a biochemically designed trial against a N-(phosphonacetyl)-L-aspartic acid-resistant variant of the Lewis lung carcinoma Cancer Research 41(3): 905-909
Lin-Chu, M.; Lee, Y.J.; Ho, M.Y. 1989: Malignant mesothelioma in infancy Archives of Pathology and Laboratory Medicine 113(4): 409-411
Murer, B. 2000: Pleural malignant mesothelioma Advances in Clinical Pathology: the Official Journal of Adriatic Society of Pathology 4(4): 177-179
Sritharan, S.S.; Frandsen, J.L.; Omland, Øy.; Bruun, J.M. 2018: Malignant pleural mesothelioma Ugeskrift for Laeger 180(15)
Shimoni, Z.; Flatau, E.; Shefer, J. 1987: Malignant mesothelioma--a difficult diagnosis Harefuah 113(5-6): 115-117
Stosiek, P.; Goertchen, R. 1986: Immunopathology of diffuse malignant mesothelioma Zentralblatt für Allgemeine Pathologie U. Pathologische Anatomie 132(2): 119-128
Razdan, J.N.; Mathur, K.C.; Bharadwaj, T.P. 1972: Diffuse malignant mesothelioma of the pleura Indian Journal of Medical Sciences 26(4): 233-235
Kaukel, E.; Koschel, G. 1991: Therapy of malignant pleural mesothelioma Medizinische Klinik 86(5): 259-262
Whitaker, D. 1977: Cell aggregates in malignant mesothelioma Acta Cytologica 21(2): 236-239
Fazekas, T.; Tiszlavicz, L.; Ungi, I. 1991: Primary malignant pericardial mesothelioma Orvosi Hetilap 132(48): 2677-2680
Doglioni, C.; Barbareschi, M.; Ferrero, S.; Buffa, R. 2000: Prognostic markers in malignant mesothelioma Advances in Clinical Pathology: the Official Journal of Adriatic Society of Pathology 4(4): 185-186
Bonfrer, J.M.; Schouwink, J.H.; Korse, C.M.; Baas, P. 1997: Cyfra 21-1 and TPA as markers in malignant mesothelioma Anticancer Research 17(4b): 2971-2973
Bakari, M.; Munseri, P.; Francis, J.; Aris, E.; Moshiro, C.; Siyame, D.; Janabi, M.; Ngatoluwa, M.; Aboud, S.; Lyamuya, E.; Sandström, E.; Mhalu, F. 2013: Experiences on recruitment and retention of volunteers in the first HIV vaccine trial in Dar es Salam, Tanzania - the phase I/Ii HIVIS 03 trial Bmc Public Health 13: 1149